CO-1686 (Rociletinib, AVL-301)
目录号: A13028
EGFR 抑制剂
CO-1686 是一种新型口服靶向共价(不可逆)抑制剂,针对致癌突变形式的表皮生长因子受体(EGFR),目前正在研究用于治疗非小细胞肺癌(NSCLC)。
| Discription | CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC). | |||||
|---|---|---|---|---|---|---|
| Targets |
|
|||||
| Cell Research |
|
| 目录号 | A13028 |
|---|---|
| 分子式 | C27H28F3N7O3 |
| 分子量 | 555.55 |
| CAS号 | 1374640-70-6 |
| SMILES | CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC |
| 其他名称 | CO1686; AVL-301; CNX-419 ;AVL 301; AVL301; CNX419 |
| 储存条件 | Store lyophilized at -20ºC, keep desiccated. |
| In vitro (25°C) | DMSO | 91 mg/mL (163.8 mM) | |
| Water | Insoluble | ||
| Ethanol | Insoluble | ||
| In vivo | 1% DMSO+30% polyethylene glycol+1% Tween 80 | 28 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 18 mL | 90 mL | 180 mL |
| 0.5 mM | 3.6 mL | 18 mL | 36 mL |
| 1 mM | 1.8 mL | 9 mL | 18 mL |
| 5 mM | 0.36 mL | 1.8 mL | 3.6 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2